Alessandro Schipani

1.2k total citations · 1 hit paper
19 papers, 948 citations indexed

About

Alessandro Schipani is a scholar working on Infectious Diseases, Pediatrics, Perinatology and Child Health and Molecular Biology. According to data from OpenAlex, Alessandro Schipani has authored 19 papers receiving a total of 948 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Infectious Diseases, 6 papers in Pediatrics, Perinatology and Child Health and 5 papers in Molecular Biology. Recurrent topics in Alessandro Schipani's work include HIV/AIDS drug development and treatment (13 papers), Pharmacological Effects and Toxicity Studies (6 papers) and Biochemical and Molecular Research (5 papers). Alessandro Schipani is often cited by papers focused on HIV/AIDS drug development and treatment (13 papers), Pharmacological Effects and Toxicity Studies (6 papers) and Biochemical and Molecular Research (5 papers). Alessandro Schipani collaborates with scholars based in United Kingdom, Switzerland and Spain. Alessandro Schipani's co-authors include Ian H. Gilbert, Paul G. Wyatt, Julie A. Frearson, Ruth Brenk, Andrew Owen, Saye Khoo, Marco Siccardi, David Back, Geraint Davies and Dolores González‐Pacanowska and has published in prestigious journals such as Journal of Medicinal Chemistry, Antimicrobial Agents and Chemotherapy and Clinical Pharmacology & Therapeutics.

In The Last Decade

Alessandro Schipani

19 papers receiving 935 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases

2007 482 citations Ruth Brenk, Alessandro Schipani et al. ChemMedChem profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alessandro Schipani United Kingdom	14	346	306	244	201	126	19	948
Victoria Barton United Kingdom	14	358 1.0×	224 0.7×	330 1.4×	316 1.6×	51 0.4×	16	1.2k
Kristina Campanale United States	10	368 1.1×	250 0.8×	91 0.4×	329 1.6×	131 1.0×	17	1.1k
Abdelhakim Ahmed‐Belkacem France	17	502 1.5×	210 0.7×	80 0.3×	173 0.9×	38 0.3×	31	1.2k
Fátima Nogueira Portugal	23	269 0.8×	132 0.4×	175 0.7×	323 1.6×	22 0.2×	82	1.2k
Edeildo Ferreira da Silva‐Júnior Brazil	23	451 1.3×	126 0.4×	188 0.8×	391 1.9×	58 0.5×	93	1.3k
Sharon Wein France	21	339 1.0×	129 0.4×	114 0.5×	270 1.3×	38 0.3×	48	1.0k
Darren Moss United Kingdom	17	234 0.7×	324 1.1×	59 0.2×	73 0.4×	148 1.2×	30	904
Onkar Singh United Kingdom	18	511 1.5×	110 0.4×	90 0.4×	248 1.2×	40 0.3×	32	999
Yingke He Singapore	13	450 1.3×	144 0.5×	183 0.8×	143 0.7×	23 0.2×	23	1.3k
Victor Meléndez United States	21	259 0.7×	126 0.4×	170 0.7×	237 1.2×	19 0.2×	39	1.2k

Countries citing papers authored by Alessandro Schipani

Since Specialization

Citations

This map shows the geographic impact of Alessandro Schipani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alessandro Schipani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alessandro Schipani more than expected).

Fields of papers citing papers by Alessandro Schipani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alessandro Schipani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alessandro Schipani. The network helps show where Alessandro Schipani may publish in the future.

Co-authorship network of co-authors of Alessandro Schipani

This figure shows the co-authorship network connecting the top 25 collaborators of Alessandro Schipani. A scholar is included among the top collaborators of Alessandro Schipani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alessandro Schipani. Alessandro Schipani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Sloan, Derek J., Alessandro Schipani, Deirdre Egan, et al.. (2017). Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis. Antimicrobial Agents and Chemotherapy. 61(7). 34 indexed citations

Olagunju, Adeniyi, Alessandro Schipani, Oluseye O. Bolaji, Saye Khoo, & Andrew Owen. (2017). Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling. Journal of Antimicrobial Chemotherapy. 73(1). 165–172. 8 indexed citations

Hu, Yanmin, Henry Pertinez, Fátima Ortega-Muro, et al.. (2016). Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model. Antimicrobial Agents and Chemotherapy. 60(8). 4778–4785. 17 indexed citations

Garner, Colin, Kevin B. Park, Neil French, et al.. (2015). Observational infant exploratory [¹⁴C]‐paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis. British Journal of Clinical Pharmacology. 80(1). 157–167. 19 indexed citations

Schipani, Alessandro, Henry Pertinez, Elizabeth Molyneux, et al.. (2015). A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children. British Journal of Clinical Pharmacology. 81(4). 679–687. 21 indexed citations

Schipani, Alessandro, David Back, Andrew Owen, et al.. (2014). Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine. Clinical Pharmacokinetics. 54(1). 107–116. 2 indexed citations

Olagunju, Adeniyi, Alessandro Schipani, Marco Siccardi, et al.. (2014). CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. Pharmacogenetics and Genomics. 24(9). 459–463. 20 indexed citations

Selby, Andrew, R.C. Garner, Caroline J. Earnshaw, et al.. (2014). ABSTRACT 707. Pediatric Critical Care Medicine. 15. 160–160. 1 indexed citations

Schipani, Alessandro, Eliseo Recio, Marcel Kaiser, et al.. (2013). Investigation of acyclic uridine amide and 5′-amido nucleoside analogues as potential inhibitors of the Plasmodium falciparum dUTPase. Bioorganic & Medicinal Chemistry. 21(18). 5876–5885. 6 indexed citations

10.

McDonald, Tom O., Marco Giardiello, Philip Martin, et al.. (2013). Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation. Advanced Healthcare Materials. 3(3). 400–411. 70 indexed citations

11.

Schipani, Alessandro, Laura Dickinson, Marta Boffito, et al.. (2012). Simultaneous Population Pharmacokinetic Modelling of Atazanavir and Ritonavir in HIV-Infected Adults and Assessment of Different Dose Reduction Strategies. JAIDS Journal of Acquired Immune Deficiency Syndromes. 62(1). 60–66. 10 indexed citations

12.

Schipani, Alessandro, Deirdre Egan, Laura Dickinson, et al.. (2012). Estimation of the Effect of Slco1B1 Polymorphisms on Lopinavir Plasma Concentration in HIV-Infected Adults. Antiviral Therapy. 17(5). 861–868. 21 indexed citations

13.

Siccardi, Marco, Lisa M. Almond, Alessandro Schipani, et al.. (2012). Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an In Vitro–In Vivo Extrapolation Model. Clinical Pharmacology & Therapeutics. 92(4). 494–502. 39 indexed citations

14.

Baragaña, Beatriz, Alessandro Schipani, Eliseo Recio, et al.. (2011). Design, Synthesis, and Evaluation of 5′‐Diphenyl Nucleoside Analogues as Inhibitors of the Plasmodium falciparum dUTPase. ChemMedChem. 6(10). 1816–1831. 28 indexed citations

15.

Schipani, Alessandro, Christoph Wyen, Tabitha Mahungu, et al.. (2011). Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. Journal of Antimicrobial Chemotherapy. 66(6). 1332–1339. 40 indexed citations

16.

Schipani, Alessandro, Marco Siccardi, Antonio D’Avolio, et al.. (2010). Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. Antimicrobial Agents and Chemotherapy. 54(12). 5242–5250. 60 indexed citations

17.

Brenk, Ruth, et al.. (2007). Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases. ChemMedChem. 3(3). 435–444. 482 indexed citations breakdown →

18.

Ruda, G.F., Alessandro Schipani, Isabel Leal, et al.. (2006). Acyclic Nucleoside Analogues as Inhibitors ofPlasmodiumfalciparumdUTPase. Journal of Medicinal Chemistry. 49(14). 4183–4195. 53 indexed citations

19.

Schipani, Alessandro, Luis M. Ruiz‐Pérez, Marcel Kaiser, et al.. (2006). Design, synthesis and evaluation of novel uracil amino acid conjugates for the inhibition of Trypanosoma cruzi dUTPase. Bioorganic & Medicinal Chemistry Letters. 16(14). 3809–3812. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact